Barriers to Hepatitis C Virus (HCV) treatment initiation in patients with human immunodeficiency virus/HCV coinfection: Lessons From the interferon era

Open Forum Infectious Diseases

Volumn 4, Issue 1, 2017, Pages

  Wansom, Tanyaporn ^a   Falade Nwulia, Oluwaseun ^a   Sutcliffe, Catherine G ^a   Mehta, Shruti H ^a   Moore, Richard D ^a   Thomas, David L ^a   Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; HCV treatment; HIV AIDS; HIV HCV coinfection

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL;

EID: 85033597996     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/OFID/OFX024     Document Type: Article

References (36)

1. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-8
2. van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144:751-760.e2
3. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 5:1408-16
4. Broz D, Wejnert C, Pham HT, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users-National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ 2014; 63:1-51
5. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658-66
6. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584-9
7. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9
8. Rodriguez-Torres M, Govindarajan S, Diago M, et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int 2009; 29:237-41
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-48
11. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361-9
12. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96
13. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88
14. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603
15. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93
16. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-61
17. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-9
18. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-31
19. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705-13
20. Wyles DL, Sulkowski MS, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/ HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60:1136a-7a
21. Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis 2012; 55:1242-51
22. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25
23. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-54
24. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714-25
25. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7
26. Mugavero MJ, Westfall AO, Cole SR, et al. Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. Clin Infect Dis 2014; 59:1471-9
27. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74
28. Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016; 62:683-94
29. Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014; 174:1974-81
30. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401
31. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801
32. Melia MT, Muir AJ, McCone J, et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011; 54:70-8
33. Wilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 2016; 63:437-44
34. Kanwal F, Kramer JR, El-Serag HB, et al. Race and gender differences in the use of direct acting antiviral agents for hepatitis C virus. Clin Infect Dis 2016; 63:291-9
35. Zinski A, Westfall AO, Gardner LI, et al. The contribution of missed clinic visits to disparities in HIV viral load outcomes. Am J Public Health 2015; 105:2068-75
36. Dale SK, Bogart LM, Wagner GJ, et al. Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV. J Health Psychol 2016; 21:1311-21